Skip to main content

Table 2 Univariate analysis of clinical variables associated with overall survival

From: Cardiac radiation dose predicts survival in esophageal squamous cell carcinoma treated by definitive concurrent chemotherapy and intensity modulated radiotherapy

Variable

Univariate analysis

HR (95% CI)

P value

Age (≤ 56 vs. >  56)

0.986 (0.639–1.522)

0.951

Gender (female vs. male)

0.710 (0.224–2.254)

0.561

Body mass index (kg/m2) (≤ 21.3 vs. >  21.3)

1.699 (1.096–2.634)

0.018

Body surface area (m2) (≤1.65 vs. >  1.65)

1.614 (1.042–2.502)

0.032

ECOG performance status (0–1 vs. 2–3)

0.376 (0.210–0.672)

0.001

Stage (I&II vs. III)

0.223 (0.055–0.910)

0.036

Tumor location (U involved vs. others)

0.733 (0.473–1.136)

0.165

Smoking (no vs. yes)

0.744 (0.358–1.547)

0.428

Alcohol (no vs. yes)

0.529 (0.214–1.310)

0.169

Hypertension (no vs. yes)

1.002 (0.587–1.710)

0.994

Diabetes (no vs. yes)

0.624 (0.335–1.160)

0.136

Cardiovascular disease (no vs. yes)

0.919 (0.336–2.518)

0.870

Heart volume (ml) (≤592 vs > 592)

1.468 (0.947–2.276)

0.086

Chemotherapy regimen (F vs. NF)

0.318 (0.150–0.673)

0.003

Radiation dose (Gy) (≤ 61.2 vs. >  61.2)

1.451 (0.924–2.280)

0.106

PTV prescribed to 36 Gy (ml) (continuous)

1.001 (1.000–1.001)

0.055

PTV prescribed to 50 Gy (ml) (continuous)

1.001 (1.000–1.002)

0.004

  1. Abbreviations: ECOG Eastern Cooperative Oncology Group, F Fluoropyrimidine-based, NF Not fluoropyrimidine-based, PTV Planning target volume, U Upper thoracic and cervical esophagus